A phase II study to evaluate ARV 471 in the neoadjuvant setting in early breast cancer patients
Latest Information Update: 12 May 2022
At a glance
- Drugs Vepdegestrant (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- 05 May 2022 According to an Arvinas media release, this study expected to initiate in 2H 2022.
- 05 Aug 2021 According to an Arvinas media release, company expects to initiate this study in second half of 2021.
- 27 Jul 2021 New trial record